Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue.
The post At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected appeared first on MedCity News.
